Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists

被引:97
作者
Klein, ES
Pino, ME
Johnson, AT
Davies, PJA
Nagpal, S
Thacher, SM
Krasinski, G
Chandraratna, AS
机构
[1] ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT BIOL, IRVINE, CA 92715 USA
[2] ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT CHEM, IRVINE, CA 92715 USA
[3] UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77225 USA
[4] UNIV TEXAS, SCH MED, DEPT MED, HOUSTON, TX 77225 USA
关键词
D O I
10.1074/jbc.271.37.22692
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inverse agonists are ligands that are capable of repressing basal receptor activity in the absence of an agonist. We have designed a series of C-1-substituted acetylenic retinoids that exhibit potent antagonism of retinoic acid receptor (RAR)-mediated transactivation. Comparison of these related retinoid antagonists for their ability 60 repress basal RAR transcriptional activity demonstrates that the identity of the C-1 substituent differentiates these ligands into two groups: RAR inverse agonists and neutral antagonists, We show that treatment of cultured human keratinocytes with a RAR inverse agonist, but not a RAR neutral antagonist, leads to the repression of the serum-induced differentiation marker MRP-8. While RAR-selective agonists also repress expression of MRP-8, cotreatment with a RAR inverse agonist and a RAR agonist results in a mutual repression of their individual inhibitory activities, indicating the distinct modes of action of these two disparate retinoids in modulating MRP-8 expression, Our data indicate that RARs, like beta(2)-adrenoreceptors, are sensitive to inverse agonists and that this new class of retinoids will provide insight into the molecular mechanisms of RAR function in skin and other responsive tissues.
引用
收藏
页码:22692 / 22696
页数:5
相关论文
共 34 条
[1]  
ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625
[2]   PHYSIOLOGICAL-EFFECTS OF INVERSE AGONISTS IN TRANSGENIC MICE WITH MYOCARDIAL OVEREXPRESSION OF THE BETA(2)-ADRENOCEPTOR [J].
BOND, RA ;
LEFF, P ;
JOHNSON, TD ;
MILANO, CA ;
ROCKMAN, HA ;
MCMINN, TR ;
APPARSUNDARAM, S ;
HYEK, MF ;
KENAKIN, TP ;
ALLEN, LF ;
LEFKOWITZ, RJ .
NATURE, 1995, 374 (6519) :272-276
[3]   THE USE OF PROGESTERONE ANTAGONISTS IN COMBINATION WITH PROSTAGLANDIN FOR TERMINATION OF PREGNANCY [J].
BYGDEMAN, M ;
SWAHN, ML ;
GEMZELLDANIELSSON, K ;
GOTTLIEB, C .
HUMAN REPRODUCTION, 1994, 9 :121-125
[4]   FUNCTIONAL EVIDENCE FOR LIGAND-DEPENDENT DISSOCIATION OF THYROID-HORMONE AND RETINOIC ACID RECEPTORS FROM AN INHIBITORY CELLULAR FACTOR [J].
CASANOVA, J ;
HELMER, E ;
SELMIRUBY, S ;
QI, JS ;
AUFLIEGNER, M ;
DESAIYAJNIK, V ;
KOUDINOVA, N ;
YARM, F ;
RAAKA, BM ;
SAMUELS, HH .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (09) :5756-5765
[5]   HIGH-EFFICIENCY TRANSFORMATION OF MAMMALIAN-CELLS BY PLASMID DNA [J].
CHEN, C ;
OKAYAMA, H .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (08) :2745-2752
[6]   A TRANSCRIPTIONAL CO-REPRESSOR THAT INTERACTS WITH NUCLEAR HORMONE RECEPTORS [J].
CHEN, JD ;
EVANS, RM .
NATURE, 1995, 377 (6548) :454-457
[7]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[8]  
CHIDIAC P, 1994, MOL PHARMACOL, V45, P490
[9]  
COSTA T, 1992, MOL PHARMACOL, V41, P549
[10]  
DELEAN A, 1980, J BIOL CHEM, V255, P7108